Functionalized Dendrimers as Nanoscale Drug Carriers

  • Rohit Kolhatkar
  • Deborah Sweet
  • Hamidreza Ghandehari
Part of the Fundamental Biomedical Technologies book series (FBMT, volume 4)

Dendrimers represent a unique class of nanostructures, playing an important role in the field of nanobiotechnology. The term dendrimer is derived from Greek (dendra means tree and meros means part) and describes highly branched three-dimensional structures. The dendritic architecture was first reported in the late 1970s and the early 1980s by the research groups of Vogtle, Denkwalter, Tomalia, and Newkome (Lee 2005). Poly(amidoamine) (PAMAM) dendrimers were the first to be synthesized and developed in Dow Laboratories between 1979 and 1985. After patents on this new technology had been filed, the dendritic architecture was presented to the public by Tomalia in 1983. Although met with initial skepticism as most new scientific inventions are, dendrimers were soon accepted, and by 1991 the number of dendrimer-related publications and presentations began to climb rapidly (Tomalia and Frechet 2001).


Boron Neutron Capture Therapy Folate Receptor PAMAM Dendrimers Oral Drug Delivery Betamethasone Valerate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agashe, H.B., et al., 2006. Investigations of the toxicological profile of functionalized fifth-generation poly(propylene imine) dendrimer. J Pharm Pharmacol, 58(11): 1491–8.PubMedGoogle Scholar
  2. Agrawal, P., U. Gupta, and N.K. Jain, 2007. Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials, 28(22): 3349–59.PubMedGoogle Scholar
  3. Ahn, T.S., et al., 2006. Light-harvesting in carbonyl-terminated phenylacetylene dendrimers: the role of delocalized excited states and the scaling of light-harvesting efficiency with dendrimer size. J Phys Chem B Condens Matter Mater Surf Interfaces Biophys, 110(40): 19810–9.PubMedGoogle Scholar
  4. Andre, S., et al., 1999. Lactose-containing Starburst dendrimers: influence of dendrimer generation and binding-site orientation of receptors (plant/animal lectins and immunoglobulins) on binding properties. Glycobiology, 9(11): 1253–61.PubMedGoogle Scholar
  5. Ashton, P.R., et al., 1997. Synthesis of glycodendrimers by modification of poly(propylene imine) dendrimers. Chem–Eur J, 3(6): 974–84.Google Scholar
  6. Beezer, A.E., et al., 2003. Dendrimers as potential drug carriers: encapsulation of acidic hydrophobes within water soluble PAMAM derivatives. Tetrahedron, 59: 3873–80.Google Scholar
  7. Bhadra, D., et al., 2003. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm, 257(1/2): 111–24.PubMedGoogle Scholar
  8. Bosman, A.W., H.M. Janssen, and E.W. Meijer, 1999. About dendrimers: structure, physical properties, and applications. Chem Rev, 99(7): 1665–88.PubMedGoogle Scholar
  9. Chandrasekar, D., et al., 2007. Folate coupled poly(ethyleneglycol) conjugates of anionic poly(amidoamine) dendrimer for inflammatory tissue specific drug delivery. J Biomed Mater Res A, 82(1): 92–103.PubMedGoogle Scholar
  10. Chauhan, A.S., et al., 2003. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. J Control Release, 90(3): 335–43.PubMedGoogle Scholar
  11. Couck, P., et al., 2005. Evaluation of the stratus CS fluorometer for the determination of plasma myoglobin. Acta Clin Belg, 60(2): 75–8.PubMedGoogle Scholar
  12. Crampton, H.L. and E.E. Simanek, 2007. Dendrimers as drug delivery vehicles: non-covalent interactions of bioactive compounds with dendrimers. Polym Int, 56: 489–96.Google Scholar
  13. D’Emanuele, A. and D. Attwood, 2005. Dendrimer–drug interactions. Adv Drug Deliv Rev, 57(15): 2147–62.PubMedGoogle Scholar
  14. D’Emanuele, A., et al., 2004. The use of a dendrimer–propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release, 95(3): 447–53.PubMedGoogle Scholar
  15. Delort, E., et al., 2006. Synthesis and activity of histidine-containing catalytic peptide dendrimers. J Org Chem, 71(12): 4468–80.PubMedGoogle Scholar
  16. Devarakonda, B., et al., 2005. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int J Pharm, 304(1/2): 193–209.PubMedGoogle Scholar
  17. Dhanikula, R.S. and P. Hildgen, 2007. Influence of molecular architecture of polyether-co-polyester dendrimers on the encapsulation and release of methotrexate. Biomaterials, 28(20): 3140–52.PubMedGoogle Scholar
  18. Dufes, C., I.F. Uchegbu, and A.G. Schatzlein, 2005. Dendrimers in gene delivery. Adv Drug Deliv Rev, 57(15): 2177–202.PubMedGoogle Scholar
  19. Duncan, R. and L. Izzo, 2005. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev, 57(15): 2215–37.PubMedGoogle Scholar
  20. Dutta, T. and N.K. Jain, 2007. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly(propyleneimine) dendrimer. Biochim Biophys Acta, 1770(4): 681–6.PubMedGoogle Scholar
  21. Dutta, T., et al., 2007. Poly(propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J Drug Target, 15(1): 89–98.PubMedGoogle Scholar
  22. Eichman, J.D., et al., 2003. The use of PAMAM dendrimers in the efficient transfer of genetic material into cells. Pharm Sci Technol Today, 3(7): 232–45.Google Scholar
  23. El-Sayed, M., et al., 2002. Transepithelial transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers. J Control Release, 81(3): 355–65.PubMedMathSciNetGoogle Scholar
  24. El-Sayed, M., et al., 2003. Influence of surface chemistry of poly(amidoamine) dendrimers on Caco-2 cell monolayers. J Bioactive Compat Polym, 18: 7–21.MathSciNetGoogle Scholar
  25. El-Sayed, M., et al., 2003. Transport mechanism(s) of poly(amidoamine) dendrimers across Caco-2 cell monolayers. Int J Pharm, 265(1/2): 151–7.PubMedGoogle Scholar
  26. Esfand, R. and D.A. Tomalia, 2001. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today, 6(8): 427–36.PubMedGoogle Scholar
  27. Fahmy, T.M., J.P. 2007. Schneck, and W.M. Saltzman, A nanoscopic multivalent antigen-presenting carrier for sensitive detection and drug delivery to T cells. Nanomedicine, 3(1): 75–85.Google Scholar
  28. Florence, A. (Ed.), 2005. Dendrimers: a versatile targeting platform. Adv Drug Deliv Rev, 57(15): 2101–286.Google Scholar
  29. Gillies, E.R. and J.M. Frechet, 2002. Designing macromolecules for therapeutic applications: polyester dendrimer–poly(ethylene oxide) “bow-tie” hybrids with tunable molecular weight and architecture. J Am Chem Soc, 124(47): 14137–46.PubMedGoogle Scholar
  30. Gillies, E.R., et al., 2005. Biological evaluation of polyester dendrimer: poly(ethylene oxide) “bow-tie” hybrids with tunable molecular weight and architecture. Mol Pharm, 2(2): 129–38.PubMedMathSciNetGoogle Scholar
  31. Gong, L.Z., Q.S. Hu, and L. Pu, 2001. Optically active dendrimers with a binaphthyl core and phenylene dendrons: light harvesting and enantioselective fluorescent sensing. J Org Chem, 66(7): 2358–67.PubMedGoogle Scholar
  32. Gupta, U., et al., 2006. A review of in vitro–in vivo investigations on dendrimers: the novel nanoscopic drug carriers. Nanomedicine, 2(2): 66–73.PubMedGoogle Scholar
  33. Haba, Y., et al., 2005. Synthesis of biocompatible dendrimers with a peripheral network formed by linking of polymerizable groups. Polymer, 46: 1813–20.MathSciNetGoogle Scholar
  34. Hawker, C.J. and J.M. Frechet, 1990. Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J Am Chem Soc, 112: 7638–47.Google Scholar
  35. Hong, S., et al., 2007. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol, 14(1): 107–15.PubMedGoogle Scholar
  36. Huang, R.Q., et al., 2007. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J, 21(4): 1117–25.PubMedGoogle Scholar
  37. Islam, M.T., I.J. Majoros, and J.R. Baker Jr., 2005. HPLC analysis of PAMAM dendrimer based multifunctional devices. J Chromatogr B Anal Technol Biomed Life Sci, 822(1/2): 21–6.Google Scholar
  38. Jansen, J.F.G.A., E.M.M. 1994. Debrabandervandenberg, and E.W. Meijer, Encapsulation of guest molecules into a dendritic box. Science, 266: 1226–9.Google Scholar
  39. Jevprasesphant, R., et al., 2003a. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm Res, 20(10): 1543–50.PubMedGoogle Scholar
  40. Jevprasesphant, R., et al., 2003b. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm, 252(1/2): 263–6.PubMedGoogle Scholar
  41. Jevprasesphant, R., et al., 2004. Transport of dendrimer nanocarriers through epithelial cells via the transcellular route. J Control Release, 97(2): 259–67.PubMedGoogle Scholar
  42. Kabanov, V.A., et al., 1998. Polyelectrolyte behavior of astramol poly(propyleneimine) dendrimers. Macromolecules, 31(15): 5142–4.PubMedADSGoogle Scholar
  43. Kitchens, K.M., M.E. El-Sayed, and H. Ghandehari, 2005. Transepithelial and endothelial transport of poly(amidoamine) dendrimers. Adv Drug Deliv Rev, 57(15): 2163–76.PubMedGoogle Scholar
  44. Kitchens, K.M., et al., 2006. Transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers: influence of size, charge and fluorescent labeling. Pharm Res, 23(12): 2818–26.PubMedGoogle Scholar
  45. Kitchens, K.M., et al., 2005. Endocytosis and interaction of poly(amidoamine) dendrimers with caco-2 cells. Pharm Res, 24(11): 2138–2145.Google Scholar
  46. Kitchens, K.M., et al., Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells. Mol Pharm, in press.Google Scholar
  47. Kobayashi, H. and M.W. Brechbiel, 2005. Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev, 57(15): 2271–86.PubMedGoogle Scholar
  48. Kobayashi, H., et al., 2004. Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin Cancer Res, 10(22): 7712–20.PubMedGoogle Scholar
  49. Kojima, C., et al., 2000. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug Chem, 11(6): 910–7.PubMedMathSciNetGoogle Scholar
  50. Kolhatkar, R.B., et al., 2007. Surface acetylation of poly(amidoamine) (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug Chem, 18(6): 2054–2060.PubMedGoogle Scholar
  51. Kolhe, P., et al., 2004. Hyperbranched polymer–drug conjugates with high drug payload for enhanced cellular delivery. Pharm Res, 21(12): 2185–95.PubMedGoogle Scholar
  52. Kolhe, P., et al., 2006. Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload. Biomaterials, 27(4): 660–9.PubMedGoogle Scholar
  53. Konda, S.D., et al., 2000. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress. Invest Radiol, 35(1): 50–7.PubMedGoogle Scholar
  54. Konda, S.D., et al., 2001. Specific targeting of folate–dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. Magma, 12(2/3): 104–13.PubMedGoogle Scholar
  55. Koyama, Y., et al., 2007. A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J Magn Reson Imaging, 25(4): 866–71.PubMedMathSciNetGoogle Scholar
  56. Langereis, S., et al., 2006. Evaluation of Gd(III) DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging. NMR Biomed, 19(1): 133–41.PubMedGoogle Scholar
  57. Lee, C.C., et al., 2005. Designing dendrimers for biological applications. Nat Biotechnol, 23(12): 1517–26.PubMedGoogle Scholar
  58. Lee, C.C., et al., 2006. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci USA, 103(45): 16649–54.PubMedADSGoogle Scholar
  59. Liu, M., K. Kono, and J.M. Frechet, 2000. Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J Control Release, 65(1/2): 121–31.PubMedGoogle Scholar
  60. Ma, M., et al., 2007. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug. Eur J Med Chem, 42(1): 93–8.PubMedGoogle Scholar
  61. Maeda, H., et al., 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release, 65(1/2): 271–84.PubMedGoogle Scholar
  62. Majoros, I.J., et al., 2005. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem, 48(19): 5892–9.PubMedGoogle Scholar
  63. Majoros, I.J., et al., 2006. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules, 7(2): 572–9.PubMedGoogle Scholar
  64. Malik, N., E.G. Evagorou, and R. Duncan, 1999. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs, 10(8): 767–76.PubMedGoogle Scholar
  65. Malik, N., et al., 2000. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125 I-labelled polyamidoamine dendrimers in vivo. J Control Release, 65(1/2): 133–48.PubMedMathSciNetGoogle Scholar
  66. Mamede, M., et al., 2004. Hepatocyte targeting of 111 In-labeled oligo-DNA with avidin or avidin-dendrimer complex. J Control Release, 95(1): 133–41.PubMedGoogle Scholar
  67. Manunta, M., et al., 2004. Gene delivery by dendrimers operates via a cholesterol dependent pathway. Nucleic Acids Res, 32(9): 2730–9.PubMedGoogle Scholar
  68. Markatou, E., et al., 2007. Molecular interactions between dimethoxycurcumin and PAMAM dendrimer carriers. Int J Pharm, 339(1/2): 231–6.PubMedGoogle Scholar
  69. McCarthy, T.D., et al., 2005. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm, 2(4): 312–8.PubMedMathSciNetGoogle Scholar
  70. Milhem, O.M., et al., 2000. Polyamidoamine Starburst dendrimers as solubility enhancers. Int J Pharm, 197(1/2): 239–41.PubMedGoogle Scholar
  71. Miura, N., et al., 1999. Complex formation by electrostatic interaction between carboxyl-terminated dendrimers and oppositely charged polyelectrolytes. Langmuir, 15(12): 4245–50.Google Scholar
  72. Muller, C., et al., 2004. Site-isolation effects in a dendritic nickel catalyst for the oligomerization of ethylene. J Am Chem Soc, 126(45): 14960–3.PubMedGoogle Scholar
  73. Na, M., et al., 2006. Dendrimers as potential drug carriers. II. Prolonged delivery of ketoprofen by in vitro and in vivo studies. Eur J Med Chem, 41(5): 670–4.PubMedGoogle Scholar
  74. Najlah, M., et al., 2007. In vitro evaluation of dendrimer prodrugs for oral drug delivery. Int J Pharm, 336(1): 183–90.PubMedGoogle Scholar
  75. Nantalaksakul, A., et al., 2006. Light harvesting dendrimers. Photosynth Res, 87(1): 133–50.PubMedGoogle Scholar
  76. Newkome, G.R., et al., 1998. Isocyanate-based dendritic building blocks: combinatorial tier construction and macromolecular-property modification. Angew Chem Int Ed, 37(3): 307–10.Google Scholar
  77. Okuda, T., et al., 2006a. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. J Control Release, 114(1): 69–77.PubMedMathSciNetGoogle Scholar
  78. Okuda, T., et al., 2006b. PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice. J Control Rel, 116(3): 330–6.MathSciNetGoogle Scholar
  79. Ooya, T., J. Lee, and K. Park, 2003. Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. J Control Release, 93(2): 121–7.PubMedGoogle Scholar
  80. Page, D., D. Zanini, and R. Roy, 1996. Macromolecular recognition: effect of multivalency on the inhibition of binding of yeast mannan to concanavalin A and pea lectins by mannosylated dendrimers. Bioorg Med Chem, 4(11): 1949–61.PubMedGoogle Scholar
  81. Paleos, C.M., et al., 2004. Acid- and salt-triggered multifunctional poly(propylene imine) dendrimer as a prospective drug delivery system. Biomacromolecules, 5(2): 524–9.PubMedGoogle Scholar
  82. Pan, G., et al., 2005. Studies on PEGylated and drug-loaded PAMAM dendrimers. J Bioactive Compat Polym, 20(1): 113–28.Google Scholar
  83. Patri, A.K., J.F. Kukowska-Latallo, and J.R. Baker Jr., 2005. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev, 57(15): 2203–14.PubMedGoogle Scholar
  84. Prieto, M.J., et al., 2006. Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic agent. Int J Pharm, 326(1/2): 160–8.PubMedGoogle Scholar
  85. Pugh, V.J., et al., 2001. Optically active BINOL core-based phenyleneethynylene dendrimers for the enantioselective fluorescent recognition of amino alcohols. J Org Chem, 66(18): 6136–40.PubMedGoogle Scholar
  86. Quintana, A., et al., 2002. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res, 19(9): 1310–6.PubMedGoogle Scholar
  87. Reek, J.N., et al., 2002. Core and periphery functionalized dendrimers for transition metal catalysis: a covalent and a non-covalent approach. J Biotechnol, 90(3/4): 159–81.PubMedGoogle Scholar
  88. Roy, R., et al., 1993. Solid-phase synthesis of dendritic sialoside inhibitors of influenza A virus haemagglutinin. J Chem Soc Chem Commun, (24): 1869–72.Google Scholar
  89. Sato, N., et al., 2003. Synthesis of dendrimer-based biotin radiopharmaceuticals to enhance whole-body clearance. Nucl Med Biol, 30(6): 617–25.PubMedGoogle Scholar
  90. Seib, F.P., A.T. Jones, and R. Duncan, 2007. Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 melanoma cells. J Control Release, 117(3): 291–300.PubMedGoogle Scholar
  91. Svenson, S. and D.A. Tomalia, 2005. Dendrimers in biomedical applications–reflections on the field. Adv Drug Deliv Rev, 57(15): 2106–29.PubMedGoogle Scholar
  92. Svobodova, L., et al., 2004. Properties of mixed alkanethiol–dendrimer layers and their applications in biosensing. Bioelectrochemistry, 63(1/2): 285–9.PubMedGoogle Scholar
  93. Tang, M.X., C.T. Redemann, and F.C. Szoka Jr., 1996. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem, 7(6): 703–14.PubMedGoogle Scholar
  94. Thomas, T.P., et al., 2005. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem, 48(11): 3729–35.PubMedGoogle Scholar
  95. Tomalia, D.A. and J.M. Frechet, Dendrimers and other dendritic polymers. Wiley, 2002.Google Scholar
  96. Tsutsumiuchi, K., K. Aoi, and M. Okada, 1999. Globular carbohydrate macromolecule “Sugar Balls” IV. Synthesis of dendritic nanocapsules with molecular recognition sites on periphery. Polym J, 31(11–1): 935–41.Google Scholar
  97. Vandamme, T.F. and L. Brobeck, 2005. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release, 102(1): 23–38.PubMedGoogle Scholar
  98. Vrasidas, I., et al., 2001. Synthesis of lactose dendrimers and multivalency effects in binding to the cholera toxin B subunit. Eur J Org Chem, 2001(24): 4685–92.Google Scholar
  99. Wada, K., et al., 2005. Improvement of gene delivery mediated by mannosylated dendrimer/alpha-cyclodextrin conjugates. J Control Release, 104(2): 397–413.PubMedGoogle Scholar
  100. Wang, J.L., et al., 2006. Nanosized gradient pi-conjugated thienylethynylene dendrimers for light harvesting: synthesis and properties. Org Lett, 8(11): 2281–4.PubMedGoogle Scholar
  101. Wang, X., et al., 2007. Synthesis, characterization, and in vitro activity of dendrimer–streptokinase conjugates. Bioconjug Chem, 18(3): 791–9.PubMedGoogle Scholar
  102. Wiwattanapatapee, R., et al., 2000. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? Pharm Res, 17(8): 991–8.PubMedGoogle Scholar
  103. Wiwattanapatapee, R., L. Lomlim, and K. Saramunee, 2003. Dendrimer conjugates for colonic delivery of 5-aminosalicylic acid. J Control Release, 88(1): 1–9.PubMedGoogle Scholar
  104. Woller, E.K., et al., 2003. Altering the strength of lectin binding interactions and controlling the amount of lectin clustering using mannose/hydroxyl-functionalized dendrimers. J Am Chem Soc, 125(29): 8820–6.PubMedGoogle Scholar
  105. Wu, G., et al., 2006a. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol Cancer Ther, 5(1): 52–9.PubMedGoogle Scholar
  106. Wu, G., et al., 2007. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin Cancer Res, 13(4): 1260–8.PubMedGoogle Scholar
  107. Wu, L., et al., 2006b. Phosphine dendrimer-stabilized palladium nanoparticles, a highly active and recyclable catalyst for the Suzuki–Miyaura reaction and hydrogenation. Org Lett, 8(16): 3605–8.PubMedGoogle Scholar
  108. Yang, H. and S.T. Lopina, 2003. Penicillin V-conjugated PEG–PAMAM star polymers. J Biomater Sci Polym Ed, 14(10): 1043–56.PubMedGoogle Scholar
  109. Yin, R., et al., 2001. Dendrimer-based alert ticket: a novel nanodevice for bio-agent detection. Polym Mater Sci Eng, 84: 856.Google Scholar
  110. Yiyun, C. and X. Tongwen, 2005a. Dendrimers as potential drug carriers. I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. Eur J Med Chem, 40(11): 1188–92.PubMedGoogle Scholar
  111. Yiyun, C. and X. Tongwen, 2005b. Solubility of nicotinic acid in polyamidoamine dendrimer solutions. Eur J Med Chem, 40(12): 1384–9.PubMedGoogle Scholar
  112. Yiyun, C., X. Tongwen, and F. Rongqiang, 2005. Polyamidoamine dendrimers used as solubility enhancers of ketoprofen. Eur J Med Chem, 40(12): 1390–3.PubMedGoogle Scholar
  113. Zeng, F. and S.C. Zimmerman, 1997. Dendrimers in supramolecular chemistry: from molecular recognition to self-assembly. Chem Rev, 97(5): 1681–712.PubMedGoogle Scholar
  114. Zhang, H., et al., 1999. Interaction of a polycation with small oppositely charged dendrimers. J Phys Chem B, 103: 2347–54.Google Scholar
  115. Zhuo, R.X., B. Du, and Z.R. Lu, 1999. In vitro release of 5-fluorouracil with cyclic core dendritic polymer. J Control Release, 57(3): 249–57.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Rohit Kolhatkar
    • 1
  • Deborah Sweet
    • 2
  • Hamidreza Ghandehari
    • 3
  1. 1.Department of Pharmaceutical SciencesUniversity of MarylandBaltimoreUSA
  2. 2.Fischell Department of BioengineeringUniversity of MarylandCollege ParkUSA
  3. 3.Department of Pharmaceutics and Pharmaceutical ChemistryUniversity of UtahSalt Lake CityUSA

Personalised recommendations